Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of Cerebrolysin therapy in pre-hospital treatment of patients with acute stroke
TCTR20220310004Phase 2Unknown
- Sponsor
- Chulalongkorn Stroke Center
- Start
- Jan 2022
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2 trial of cerebrolysin in stroke, sponsored by Chulalongkorn Stroke Center. Status: unknown.
02
Drugs
cerebrolysin
03
Conditions
stroke
Beyond the preview
Go deeper on TCTR20220310004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220310004.